Group 1 - Southbound funds reduced their holdings in Jinxin Fertility (01951.HK) by 4.7445 million shares on February 9 [1] - Over the past 5 trading days, southbound funds increased their holdings on 4 days, with a total net increase of 13.3475 million shares [1] - In the last 20 trading days, there were 13 days of net increases in holdings by southbound funds, totaling 13.3616 million shares [1] - Currently, southbound funds hold 1.47 billion shares of Jinxin Fertility, accounting for 53.31% of the company's issued ordinary shares [1] Group 2 - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 通用环球医疗集团有限公司（原名：环球医疗金融与技术咨询服务有限公司）是一家从事医疗健康业务 的中国公司。该公司主要通过两个分部运营。金融业务分部主要包括直接融资租赁、售后回租赁、保 理、经营租赁和咨询服务。医疗健康业务主要包括医疗健康服务、医院运营管理和医疗设备进出口贸易 和国内贸易、设备全周期管理和医疗数字科技服务。该公司主要在中国境内开展业务。 证券之星消息，2月9日南向资金增持100.2万股环球医疗（02666.HK）。近5个交易日中，获南向资金增 持的有5天，累计净增持632.65万股。近20个交易日中，获南向资金增持的有11天，累计净增持272.35万 股。截至目前，南向资金持有环球医疗（02666.HK）4.5亿股，占公司已发行普通股的22.35%。 ...

随着这一监督机制日益成熟，数据监管的潜力将得到进一步释放。当前，国家医保局已明确提出向"精 细管理"转型的战略方向，病种分析功能也正从"问题发现"向"标准引导"升级。这一转变尤其体现在通 过持续呈现不同医疗机构的诊疗差异，并结合医学理论解读数据内涵，为医疗机构提供更清晰的优化路 径。这种模式将有力推动医院从以往被动整改转向主动优化，激发其内生动力，以实现成本的有效控制 和质效的显著提升，从而为更大范围挤出过度检查"水分"奠定基础。 当然，在肯定医保数据监管效能的同时，仍须保持必要的警惕。数据本身是客观的，但解读数据并将结 果应用到具体的诊疗过程中，需要避免简单的"唯数据论"。毕竟，医疗行为具有高度复杂性，临床实践 中往往存在合理的个体差异。因此，医保部门在数据发布与反馈中，必须紧密结合医学专业逻辑与临床 实践需求，充分尊重医疗机构的专业判断权，通过构建建设性的专业对话平台，进一步凝聚行业共识。 数据监管的目标在于引导医疗服务更规范、更合理，而非抑制医疗领域必要的探索与创新。 通过医保数据精准挤出"水分"，有效遏制过度检查乱象，让患者免花"冤枉钱"、少做"无用检查"，切实 减轻他们的就医负担。同时，避免医保基金 ...

Core Viewpoint - The company has announced a change in the quality control reviewer for its 2025 annual audit, appointing Xu Juping in place of Wang Qichao due to internal adjustments at the auditing firm Zhonghui [1][4]. Group 1: Change in Quality Control Reviewer - The company held its 10th Board of Directors' ninth meeting on April 25, 2025, and the 2024 annual shareholders' meeting on June 5, 2025, where it approved the appointment of Zhonghui Certified Public Accountants as the auditing firm for the 2025 fiscal year [1]. - The original quality control reviewer Wang Qichao has been replaced by Xu Juping for the 2025 audit services due to internal adjustments at Zhonghui [1]. Group 2: Reviewer Background - The new quality control reviewer Xu Juping has no criminal penalties or administrative sanctions from regulatory bodies in the past three years [2]. - There are no circumstances that could affect the independence of the new quality control reviewer [3]. Group 3: Impact of Change - The transition of responsibilities during this change will be orderly, and it will not affect the financial statement audit and internal control audit for the 2025 fiscal year [4].

Core Insights - The trend of "foreigners seeking medical treatment in China" has surged since 2026, with significant attention on the efficiency and cost-effectiveness of Chinese healthcare compared to Western countries [1][15][17] - The number of international patients in key Chinese hospitals reached 1.28 million in 2025, a 73.6% increase from three years prior, indicating a growing ecosystem for international medical services [1][15] Group 1: Patient Experiences - A foreign patient, Andre, shared his experience of receiving quick and efficient treatment in a Chinese hospital, highlighting a 30-minute visit for a fishbone removal that cost only 300 RMB, contrasting sharply with longer wait times and higher costs in Australia [2][3][4] - The affordability of medical services in China is a significant draw for international patients, with cost comparisons showing treatments in China can be up to 10 times cheaper than in countries like the US and Turkey [15][16] Group 2: Medical Professionals' Perspectives - Chinese medical professionals are increasingly confident in their ability to treat international patients, as evidenced by a case where a Filipino doctor sought treatment for a patient in China, showcasing the growing recognition of Chinese medical expertise [6][7][9] - The use of advanced technologies and multi-disciplinary teams in Chinese hospitals enhances the quality of care, making it appealing for foreign patients [7][9] Group 3: Institutional Insights - The Chinese healthcare system is evolving to attract more international patients, with private hospitals seen as key players in this shift, as they can offer tailored services and flexibility that public hospitals may not [10][11] - Despite the growing interest, there is still a significant gap in brand recognition for Chinese hospitals internationally, indicating a need for improved marketing and outreach strategies [11][12] Group 4: Cost Comparisons - The cost of medical services in China is significantly lower than in many Western countries, with examples showing that a consultation in China can cost as little as 4 USD compared to hundreds or thousands in the US [16][17] - The structured pricing in China's public healthcare system contributes to its affordability, making it an attractive option for international patients seeking quality care at lower costs [16][17]

Core Viewpoint - The trend of "foreigners seeking medical treatment in China" has surged since 2026, with significant attention on the efficiency, quality, and cost-effectiveness of Chinese healthcare compared to Western countries [2][19]. Group 1: Growth in International Patients - In 2025, key foreign-related hospitals in China received 1.28 million international patients, a 73.6% increase from three years prior [2]. - By 2024, 850 medical institutions across 57 cities in China had established international medical services, forming a growing ecosystem [2]. Group 2: Patient Experiences - Foreign patients have shared positive experiences regarding the speed and efficiency of medical services in China, with one Australian patient noting a 30-minute treatment for a fishbone incident costing only 300 RMB [4][5]. - Comparatively, similar treatments in countries like Australia and Turkey can cost significantly more, highlighting the cost advantage of Chinese healthcare [19][20]. Group 3: Medical Professionals' Perspectives - Chinese medical professionals express confidence in their ability to treat foreign patients, noting that international patients are increasingly willing to seek treatment in China without hesitation [8][12]. - The use of advanced technologies and multi-disciplinary teams in Chinese hospitals enhances the quality of care provided to international patients [10][12]. Group 4: Brand and Policy Challenges - Despite the growing number of international patients, there is a need for improved brand recognition and marketing of Chinese hospitals to attract more foreign patients [14][16]. - The private healthcare sector is seen as a potential leader in accommodating international patients, while public hospitals should focus on domestic needs [16][17]. Group 5: Cost Comparison - The cost disparity between Chinese and Western medical services is significant, with reports indicating that treatment costs in China can be up to 10 times lower than in countries like the U.S. and Australia [19][20]. - The average outpatient cost in China is reported to be 361 RMB, while the U.S. healthcare expenditure per capita is significantly higher, reflecting the efficiency of China's public healthcare system [20].

当天，仁济医院还发布了AI智能外科培训、急危重症模拟训练等四大国际培训项目，打造"理论+实操 +模拟"的立体化教育体系，吸引全球医学生来华学习交流，推动中国医疗智慧与世界共享。 复旦大学附属中山医院(中山医院)方面介绍，参展WHX2026是医院综合实力的自信展示，也体现了医 院寻求广泛深入国际合作的积极姿态。该院重点分享肝脏外科、心血管疾病等传统优势学科的成熟诊疗 上海交通大学医学院附属仁济医院(简称：仁济医院)以"智慧医院整体方案"为核心，携6项重磅智慧医 疗成果亮相展览，向世界展示了中国上海在医疗健康领域的创新实力与开放姿态。 9日当天，在中国工程院院士、仁济医院院长夏强的带领下，"仁济智慧医院整体方案V1.0"全球首发。 方案涵盖了智慧手术部、智慧ICU、智慧病房和互联网医院平台等多个场景，完整勾勒出"以患者为中 心、以AI为驱动"的未来医院新范式。方案一经发布，便迅速吸引了中东、欧洲、东南亚等地区国家医 疗同行的高度关注。夏强表示，医疗出海不只是救治，更是技术共享与生命接力。 据悉，仁济医院展台上的"AI医生助理(AI Doctor Assistant, AIDA)"引来众多现场观众。据介绍，它并非 ...

外国人来华就医"火了"？21世纪经济报道记者走访发现，与网络热潮相比，现实仅有个案，但显著提升中国医疗的国际曝光度。 近期，外国人来华就医在网络上引发热议。21世纪经济报道记者走访浙江、北京部分医院发现，国际部床位和患者规模仍有限，这一现象尚未形成热潮。上 海、深圳等一线城市相关从业者透露，近期专门来华医疗旅游的外国人人数并未显著增加，和网络上传递出来的现象有差距。 21世纪经济报道记者柳宁馨 杭州报道 （浙大一院国际保健中心区域指示牌，拍摄/柳宁馨） 从部分就诊的外国患者个案反馈看，他们对在华看病的评价集中于成本、效率和技术优势。 一位在北京做英语培训的美国外教告诉21世纪经济报道记者，他觉得北京的医生特别好。他透露，之前在北京积水潭医院做了一个小手术，是个在国外很容 易被误诊的病，但积水潭医院的医生一次就看出病因，他从门诊到住院仅等了两周，整体体验特别好。 在扩大服务消费背景下，日前，国务院办公厅印发了《加快培育服务消费新增长点工作方案》，其中提到入境消费等重点领域。目前，上海、北京、深圳、 海南等地已开展国际医疗旅游试点，未来有望继续完善制度标准。 商务部国际贸易经济合作研究院研究员白明在接受21世纪经 ...

近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月9日收盘，国际医学(000516)报收于4.94元，上涨0.82%，换手率1.28%， 成交量28.17万手，成交额1.39亿元。 2月9日的资金流向数据方面，主力资金净流入285.01万元，占总成交额2.05%，游资资金净流出632.9万 元，占总成交额4.55%，散户资金净流入347.88万元，占总成交额2.5%。 该股最近90天内共有2家机构给出评级，增持评级2家；过去90天内机构目标均价为5.5。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301 ...

Group 1 - The company disclosed its 2025 annual performance forecast on January 31, 2026, indicating adherence to accounting standards [2] - The company emphasized compliance with the "Enterprise Accounting Standards" and related regulations in its financial reporting [2] - Investors are advised to refer to the company's publicly disclosed periodic reports for accurate financial information [2]